GPP
ASND icon

Great Point Partners’s Ascendis Pharma A/S ASND Stock Holding History

Great Point Partners’s Portfolio ASND Stock Details ASND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-200,000
Closed -$23.5M – 32
2019
Q1 		$23.5M Buy
+200,000
New +$17.5M 2.33% 18

Other funds holding ASND

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Great Point Partners's ASND Position: Q4 2025 in Review

Great Point Partners sold out of Ascendis Pharma A/S (ASND) in Q4 2025, closing a stake of 75,000 shares — an estimated $14.9M sold.

Great Point Partners first reported a position in ASND in Q1 2015 and held it in 8 quarters. The position peaked at $57.6M in Q2 2019. 302 funds tracked by Wall St. Rank hold ASND as of Q4 2025.

  • Great Point Partners reported no remaining Ascendis Pharma A/S position as of Q4 2025 after selling out during the quarter.
  • Great Point Partners sold 75,000 Ascendis Pharma A/S shares in Q4 2025, an estimated $14.9M.
  • Great Point Partners first reported a position in Ascendis Pharma A/S in Q1 2015 and held it in 8 quarters.
  • Great Point Partners's Ascendis Pharma A/S position peaked at $57.6M in Q2 2019.
  • 302 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q4 2025.

Based on Great Point Partners's 13F filing for Q4 2025, filed 17 Feb 2026.